Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a Pediatric Oncology Department

Condition(s) studied

Investigational drug(s) / intervention(s)

self-report questionnaires, research interviews: self-report questionnaires and research interviews

Study summary

The goal of this clinical trial is to evaluate whether the Snoezelen multisensory relaxation approach can reduce anxiety symptoms in children and adolescents aged 8 to 17 years hospitalized for chemotherapy in a pediatric oncology unit.

Researchers will compare patients' symptoms during a chemotherapy cycle with Snoezelen sessions to a previous cycle without Snoezelen, in order to assess changes in psychological and physical well-being.

Participants will:

* Be enrolled between their first (without Snoezelen) and second (with Snoezelen) chemotherapy cycles
* Complete self-report questionnaires on anxiety, depression, quality of life, and nausea
* Receive 45-minute Snoezelen sessions every two days during their second hospitalization
* Participate in a semi-structured interview after the final session
* Provide data on medications (anxiolytics, antiemetics) and vomiting frequency during both hospitalizations

Eligibility

Primary outcome measure(s)

• Semi-structured research interview — At the end of the 2nd course of chemotherapy and no more than 2 weeks after the last Snoezelen session, 1 month after inclusion
  Interview with a research psychologist to find out how teenage children feel

Trial sites (1)

More Centre Oscar Lambret trials in France

Other trials for the same condition